Vilon

Russian research shows that Vilon is a potent modulator of chromatin structure. One study found that Vilon:

• Induces chromatin unfolding
• Activates the synthetic process by reactivating ribosomal genes in unfolded chromatin
• release repressed genes, and Does not cause decondensation of chromatin in pericentromeric structures . Reduce chromatin unfolding

The end result of the changes Vilon causes in DNA is the reactivation of otherwise silenced genes. Generally, chromatin is in a wound (heterochromatin) or unwound (euchromatin) state. Heterochromatin is not accessible to the apparatus that converts genes into proteins and thus into functional components of the cell. Genes in these regions of DNA simply cannot be used for protein production.

In general, chromatin helps regulate which genes are available for transcription and is therefore one way that different cells can have different functions or the same cell can have different functions over time. Unfortunately, chromatin condensation is also a consequence of aging and senescence, and is at least one of the reasons why our cells and tissues lose function as we age.

Similar to its activity in lymphocytes, Vilon has been shown to activate interleukin-2 signaling in splenocytes. Interleukin-2 is important for coordinating immune responses to microbial infections and helps prevent autoimmune responses. By activating lymphocytes and splenocytes while enhancing natural protection against autoimmune responses, Vilon restores the immune system to a more active state and may even help develop treatments for autoimmune diseases.

Vilon’s action in the thymus enhances its ability to prevent autoimmune reactions. Thymus culture studies show that Vilon increases the proliferation of CD5 T cells. CD5 is a marker for mature T helper cells as well as cytotoxic CD8 T cells. The former helps regulate the immune system and prevent autoimmune reactions, while the latter is one of the most potent antimicrobial cells in the body.

Interestingly, Vilon appears to reactivate immune function only through genes that have been silenced by chromatin changes. It does not appear to activate genes that are naturally silenced in the cells it affects. In other words, Vilon does not turn lymphocytes into neurons by activating genes that are normally inactive in healthy lymphocytes. Instead, the peptide appears to boost immune system activity while helping to prevent autoimmune reactions.

Veron and cancer

As mentioned above, Vilon helps reduce cancer rates in mouse models, which is at least one way it increases average lifespan. Other studies have shown that Vilon not only prevents tumors from forming but also inhibits their growth once they appear. This suggests that Vilon may be an effective chemotherapy drug in its own right and a potential additive to existing cancer treatments. In the future, Vilon may become a standard addition to a variety of treatments, from chemotherapy to radiation therapy and surgery.

At least one study out of Russia refutes the idea that Vilon may be a useful adjuvant for chemotherapy. The study showed that the combination of Vilon and platinum chemotherapy drugs was problematic rather than synergistic. Unfortunately, this study only used one specific type of chemotherapy and was limited in scope, so the results cannot be generalized. It remains to be seen whether Vilon is only effective against cancer, or whether the peptide can be added to other treatment regimens to improve efficacy.

Veron and aging

Studies in mice show that subcutaneous injections of Vilon can increase physical activity and endurance while helping to reduce the risk of cancer. These two effects resulted in treated mice living longer, suggesting that Vilon may be a legitimate anti-aging peptide. This is particularly encouraging because it did not cause any side effects in mice after long-term administration.

Interestingly, studies show that the earlier Vilon is taken, the greater its effects appear to be. In other words, injecting Vilon into young mice extended lifespan more than injecting Vilon into the mice when they were older. The same effect was found in earlier studies that looked at giving mice crude thymus and pineal gland extracts to slow aging. Vilon and similar peptides are hypothesized to reverse senescence in existing cells when administered later in life, but apparently have no effect on cells that have been eliminated through apoptosis. By taking Vilon 20mg early in life, cells receive maximum protection, thus slowing down their turnover. The result is that more cells remain healthy for longer, slowing the need to replace them and preserving a limited lineage of stem cells.

Vilon’s anti-aging effects appear to extend to gastrointestinal function as well, as the peptide has been shown to improve the activity of certain enzymes in the gastrointestinal tract of older mice. The peptide also appears to improve barrier function, thereby reducing the incidence of leaky gut, increasing disease resistance, and improving the overall health of the gastrointestinal tract in aged mice. Studies show that Vilon helps improve glucose and glycine absorption in the small intestine of aged rats. These properties of Vilon may help maintain nutrient extraction as we age, thereby improving overall health and perhaps extending lifespan.

Dr. Vladimir N. Anisimov, who has studied aging and cancer development since the 1970s, notes that the thymus is one of two glands (the other is the pineal gland) that play an important role in regulating aging. The healthier the thymus, the healthier we are as individuals. Vilon, of course, is a thymosin that affects cells that are produced and mature in the thymus, such as lymphocytes. Dr. Anisimov is a strong advocate of the use of peptide biomodulators for cancer prevention. He was a close colleague of Dr. Vladimir Havenson.

Vilon in the heart and kidneys

Vilon’s effects on the vasculature have not been fully studied, but some studies suggest it may have beneficial effects. Studies in mice have shown that Vilon can alter the expression of more than 36 different genes in the heart. When combined with Epithalon, that number jumps to 144 genes. These findings suggest that at least Vilon is able to alter gene expression patterns in the cardiovascular system, a fact that may improve hemodynamic function.

In fact, studies in the kidney, a highly vascular organ, show that Vilon reduces the concentration of transforming growth factor-beta(1), thereby reducing microvascular permeability. The end result was improved hemostasis during renal failure, suggesting that Vilon actually has beneficial effects on the vasculature.

Additionally, studies in older patients with diabetes show that Vilon can help optimize coagulation by increasing levels of the natural anticoagulants antithrombin III and protein C, while stimulating fibrinolysis. The result is fewer blood clots in people prone to clotting, with attendant serious consequences. This further supports the idea that Vilon plays an important role in regulating the vasculature.

Veron summary

Vilon is a potent immune modulator and anti-aging peptide with numerous studies supporting its benefits. There is also substantial evidence that Vilon may reduce the risk of cancer development and progression. Interestingly, Vilon appears to provide better anti-aging and anti-cancer effects when taken at low doses early in life and over long periods of time. These characteristics may help open the door to better anti-aging research and help scientists better understand how epigenetic regulation plays an important role in longevity.